Stay Ahead in Fast-Growing Economies.
Browse Reports Now
Chronic Myeloid Leukemia Treatment Market Growth Analysis & Forecast (2024-2032)
The Chronic Myeloid Leukemia (CML) Treatment market is centered on devices, drugs, and methods utilized to care for and treat CML, a type of blood cancer characterized by genetic mutations in the bone marrow.
IMR Group
Description
Chronic Myeloid Leukemia Treatment Market Synopsis:
Chronic Myeloid Leukemia Treatment Market Size Was Valued at USD 8.59 Billion in 2023, and is Projected to Reach USD 16.33 Billion by 2032, Growing at a CAGR of 7.4 % From 2024-2032.
The Chronic Myeloid Leukemia (CML) Treatment market is centered on devices, drugs, and methods utilized to care for and treat CML, a type of blood cancer characterized by genetic mutations in the bone marrow. It covers molecular therapy chemotherapy, and additional supportive care, including a notable focus on tyrosine kinase inhibitors (TKI), which are the core of CML treatment options.
This market is expected to grow at a constant rate, primarily from the advanced research in the precision medicine market and the increasing incidence rate of leukemia globally. Patient awareness and diagnostic equipment accessibility cause increased disease awareness, and the need for better medications and more effective treatment – early diagnosis is such a reason. Governments and other healthcare entities are investing in research on the newer generation of therapies, which drives the market’s expansion.
The availability of second-generation TKIs that can effectively treat first-line treatment-resistant patients is another source of growth. They give enhanced prognosis, better prognosis, and enhanced quality of life to these patients. Further, new types of supportive care therapies like hematopoietic growth factors and immune modulators are included in the treatment. However, the current treatment is costly, and some treatments have side effects which mostly deals with the third world areas.
Chronic Myeloid Leukemia Treatment Market Trend Analysis:
Growing Focus on Personalized Medicine in CML Treatment
The idea of personalized Medicine is gradually making its way in the treatment of CML especially if the therapies are based on the DNA profile and status of the patient. The accuracy of identifying the presence of the Philadelphia chromosome – one of the biochemical markers of CML – with the help of PCR tests is high. This allows the best of the therapies such as TKIs to be properly administered in patients with specific characteristics.
With biomarker and resistance mechanisms’ constant study, opportunities to renew and diversify treatments are emerging. Additional anticancer treatment programs using TKIs together with immunomodulators to manage drug resistance and optimize long-term outcomes are also underway, which must be regarded as an important tendency in individualization.
Expanding Access to CML Treatment in Emerging Markets
The CML Treatment Market has high potential primarily because of the large volume of subjects in these areas as the medical infrastructure is being established. Authorities of these areas are integrating policies that will enhance the availability of cancer treatment including those over… affordable charges and partnerships with pharmaceutical research. There are also efforts made to attempt to conduct the generic TKIs, and this is now making the status of the treatment procedure from the reachable flamboyant advance therapeutics from the different regions within low- and middle-income countries.
There has also been an emphasis on measures creating awareness or starting programs that make sure that parents and often health care professionals can recognize the symptoms associated with the disease early enough, or know the treatments available in the market, a factor that drives the market in these regions.
Chronic Myeloid Leukemia Treatment Market Segment Analysis:
Chronic Myeloid Leukemia Treatment Market is Segmented on the basis of Drug Type, Route of Administration, Distribution Channel, and Region.
By Drug Type, the Tyrosine kinase segment is expected to dominate the market during the forecast period
It looks like the Tyrosine Kinase segment dominates the CML Treatment Market at present, thanks to the finding that TKIs are quite effective and safe in attempting to target one of the mutations that causes this form of disease. These TKIs like imatinib dasatinib and nilotinib are real differences in CML through better tolerated long-term response and improved survival rates.
Certain advances are new-generation TKIs intended for drug resistance to first-line treatment and for enhanced subjective tolerance levels. They are now regarded as the initial line of treatment for CML patients with persistent research of other molecules building the foundation of the market. The TKI segment has also been pushed up because of improved access due to new TKI brands and generics, especially in certain regions that are sensitive to cost.
By Route of Administration, Oral segment expected to held the largest share
The Oral segment is anticipated to have the largest market share due to its uses, patients’ preferences, and delivery by formulation. This has made Oral TKIs the most common treatment since it allows patients’ lives to be normal without having to spend most of their time in the hospital.
Apart from pharmacokinetics, the establishment of once-a-day dosing cycles has dignified oral drugs even more. These include improved disease management, reduced costs to the delivery of health care, and enhanced quality of patient’s lives. Opportunities of self-injection and possibilities to utilize oral formulations in the frame of the developing countries can also be considered as stimulating this segment.
Chronic Myeloid Leukemia Treatment Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
The region can boast a leadership position credited to its equipped healthcare facilities, high frequency of CML-diagnosed cases, high apex and commitment to research activities. Specifically, the high market share of the United States stems from enhanced uptake of next-generation TKIS, enhanced insurance reimbursement on cancer-related ailments, and aggressive investment in cancer research. Therefore, there is efforts such as the Cancer Moonshot developed by the government to combat cancer that will enhance and increase the accessibility of CML treatment.
Canada also contributes to the region’s strength in form of a shift towards their use of more personal health as well as better diagnosing. This is especially the case thanks to the presence of numerous large pharmaceutical companies coupled with favorable supportive legislation of bio-drug development. In the same way, coupled with the programs of awareness, other support activities that have been initiated to help CML patient have placed North America at a vantage position to diagnose the disease early, and strictly follow the right treatment procedures.
Active Key Players in the Chronic Myeloid Leukemia Treatment Market:
Amgen Inc. (USA)
Ariad Pharmaceuticals, Inc. (USA)
Ascentage Pharma (China)
AstraZeneca (UK)
Bayer AG (Germany)
Bristol-Myers Squibb (USA)
Cellectis (France)
Celgene Corporation (USA)
F. Hoffmann-La Roche AG (Switzerland)
Gilead Sciences, Inc. (USA)
Johnson & Johnson (USA)
Merck & Co., Inc. (USA)
Novartis AG (Switzerland)
Pfizer Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan), and Other Active Players
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter’s Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Chronic Myeloid Leukemia Treatment Market by Drug Type
4.1 Chronic Myeloid Leukemia Treatment Market Snapshot and Growth Engine
4.2 Chronic Myeloid Leukemia Treatment Market Overview
4.3 Tyrosine Kinase Inhibitors Imatinib Dasatinib
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Tyrosine Kinase Inhibitors Imatinib Dasatinib: Geographic Segmentation Analysis
4.4 Nilotinib Bosutinib
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Nilotinib Bosutinib: Geographic Segmentation Analysis
4.5 Ponatinib
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Ponatinib: Geographic Segmentation Analysis
4.6 Asciminib
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Asciminib: Geographic Segmentation Analysis
4.7 Others Antimetabolites Others
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others Antimetabolites Others: Geographic Segmentation Analysis
Chapter 5: Chronic Myeloid Leukemia Treatment Market by Route of Administration
5.1 Chronic Myeloid Leukemia Treatment Market Snapshot and Growth Engine
5.2 Chronic Myeloid Leukemia Treatment Market Overview
5.3 Oral Parenteral Topical Others
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral Parenteral Topical Others: Geographic Segmentation Analysis
Chapter 6: Chronic Myeloid Leukemia Treatment Market by Distribution channel
6.1 Chronic Myeloid Leukemia Treatment Market Snapshot and Growth Engine
6.2 Chronic Myeloid Leukemia Treatment Market Overview
6.3 Hospital Pharmacies Retail Pharmacies Online Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies Retail Pharmacies Online Pharmacies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Chronic Myeloid Leukemia Treatment Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 AMGEN INC. (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ARIAD PHARMACEUTICALS INC. (USA)
7.4 ASCENTAGE PHARMA (CHINA)
7.5 ASTRAZENECA (UK)
7.6 BAYER AG (GERMANY)
7.7 BRISTOL-MYERS SQUIBB (USA)
7.8 CELLECTIS (FRANCE)
7.9 CELGENE CORPORATION (USA)
7.10 F. HOFFMANN-LA ROCHE AG (SWITZERLAND)
7.11 GILEAD SCIENCES INC. (USA)
7.12 JOHNSON & JOHNSON (USA)
7.13 MERCK & CO. INC. (USA)
7.14 NOVARTIS AG (SWITZERLAND)
7.15 PFIZER INC. (USA)
7.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Chronic Myeloid Leukemia Treatment Market By Region
8.1 Overview
8.2. North America Chronic Myeloid Leukemia Treatment Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Type
8.2.4.1 Tyrosine Kinase Inhibitors Imatinib Dasatinib
8.2.4.2 Nilotinib Bosutinib
8.2.4.3 Ponatinib
8.2.4.4 Asciminib
8.2.4.5 Others Antimetabolites Others
8.2.5 Historic and Forecasted Market Size By Route of Administration
8.2.5.1 Oral Parenteral Topical Others
8.2.6 Historic and Forecasted Market Size By Distribution channel
8.2.6.1 Hospital Pharmacies Retail Pharmacies Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Chronic Myeloid Leukemia Treatment Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Type
8.3.4.1 Tyrosine Kinase Inhibitors Imatinib Dasatinib
8.3.4.2 Nilotinib Bosutinib
8.3.4.3 Ponatinib
8.3.4.4 Asciminib
8.3.4.5 Others Antimetabolites Others
8.3.5 Historic and Forecasted Market Size By Route of Administration
8.3.5.1 Oral Parenteral Topical Others
8.3.6 Historic and Forecasted Market Size By Distribution channel
8.3.6.1 Hospital Pharmacies Retail Pharmacies Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Chronic Myeloid Leukemia Treatment Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Type
8.4.4.1 Tyrosine Kinase Inhibitors Imatinib Dasatinib
8.4.4.2 Nilotinib Bosutinib
8.4.4.3 Ponatinib
8.4.4.4 Asciminib
8.4.4.5 Others Antimetabolites Others
8.4.5 Historic and Forecasted Market Size By Route of Administration
8.4.5.1 Oral Parenteral Topical Others
8.4.6 Historic and Forecasted Market Size By Distribution channel
8.4.6.1 Hospital Pharmacies Retail Pharmacies Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Chronic Myeloid Leukemia Treatment Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Type
8.5.4.1 Tyrosine Kinase Inhibitors Imatinib Dasatinib
8.5.4.2 Nilotinib Bosutinib
8.5.4.3 Ponatinib
8.5.4.4 Asciminib
8.5.4.5 Others Antimetabolites Others
8.5.5 Historic and Forecasted Market Size By Route of Administration
8.5.5.1 Oral Parenteral Topical Others
8.5.6 Historic and Forecasted Market Size By Distribution channel
8.5.6.1 Hospital Pharmacies Retail Pharmacies Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Chronic Myeloid Leukemia Treatment Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Type
8.6.4.1 Tyrosine Kinase Inhibitors Imatinib Dasatinib
8.6.4.2 Nilotinib Bosutinib
8.6.4.3 Ponatinib
8.6.4.4 Asciminib
8.6.4.5 Others Antimetabolites Others
8.6.5 Historic and Forecasted Market Size By Route of Administration
8.6.5.1 Oral Parenteral Topical Others
8.6.6 Historic and Forecasted Market Size By Distribution channel
8.6.6.1 Hospital Pharmacies Retail Pharmacies Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Chronic Myeloid Leukemia Treatment Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Type
8.7.4.1 Tyrosine Kinase Inhibitors Imatinib Dasatinib
8.7.4.2 Nilotinib Bosutinib
8.7.4.3 Ponatinib
8.7.4.4 Asciminib
8.7.4.5 Others Antimetabolites Others
8.7.5 Historic and Forecasted Market Size By Route of Administration
8.7.5.1 Oral Parenteral Topical Others
8.7.6 Historic and Forecasted Market Size By Distribution channel
8.7.6.1 Hospital Pharmacies Retail Pharmacies Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
Q1: What would be the forecast period in the Chronic Myeloid Leukemia Treatment Market Research report?
A1: The forecast period in the Chronic Myeloid Leukemia Treatment Market Research Report is 2024-2032.
Q2: Who are the key players in the Chronic Myeloid Leukemia Treatment Market?
A2: Amgen Inc. (USA), Ariad Pharmaceuticals, Inc. (USA), Ascentage Pharma (China), AstraZeneca (UK), Bayer AG (Germany), Bristol-Myers Squibb (USA), Cellectis (France), Celgene Corporation (USA), F. Hoffmann-La Roche AG (Switzerland), Gilead Sciences, Inc. (USA), Johnson & Johnson (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Pfizer Inc. (USA), Takeda Pharmaceutical Company Limited (Japan), and Other Active Players
Q3: What are the segments of the Chronic Myeloid Leukemia Treatment Market?
A3: The Chronic Myeloid Leukemia Treatment Market is segmented into Drug Type, Route of Administration, Distribution Channel, and region. By Drug Type, the market is categorized into Tyrosine Kinase Inhibitors, Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, Asciminib, and Other Antimetabolites. By Route of administration, the market is categorized into Oral, Parenteral, Topical Others. By Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Q4: What is the Chronic Myeloid Leukemia Treatment Market?
A4: The Chronic Myeloid Leukemia (CML) Treatment market is centered on devices, drugs, and methods utilized to care for and treat CML, a type of blood cancer characterized by genetic mutations in the bone marrow. It covers molecular therapy chemotherapy, and additional supportive care, including a notable focus on tyrosine kinase inhibitors (TKI), which are the core of CML treatment options.
Q5: How big is the Chronic Myeloid Leukemia Treatment Market?
A5: Chronic Myeloid Leukemia Treatment Market Size Was Valued at USD 8.59 Billion in 2023, and is Projected to Reach USD 16.33 Billion by 2032, Growing at a CAGR of 7.4 % From 2024-2032.
How to Buy a Report from eminsights.jp
On the product page, choose the license you want: Single-User License, Multi-User License or Enterprise License.
If you required report in your native language, then you can click on Translated Report button and fill out the form with report name and language you want, then our team will contact you as soon as possible.
Click the Buy Now button.
You will be redirected to the checkout page. Enter your company details and payment information.
Click Place Order to complete the purchase.
Confirmation: You’ll receive an order confirmation and our team will contact you shortly with your ordered report.
If you have any questions, fill out the contact form below or email us at bizdev@eminsights.net.
Thank you for choosing eminsights.jp!
